1,820
Participants
Start Date
August 7, 2013
Primary Completion Date
April 30, 2018
Study Completion Date
April 30, 2018
Sirukumab 100 mg
Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
Sirukumab 50 mg
Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
Placebo
Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
Birmingham
Glendale
Mesa
Peoria
Phoenix
Covina
El Cajon
Glendale
Hemet
Huntington Beach
La Jolla
La Palma
Placentia
Upland
Victorville
Whittier
Hamden
Aventura
Boca Raton
Brandon
Daytona Beach
DeBary
Miami
Orlando
Palm Harbor
Plantation
Sarasota
Tampa
Zephyrhills
Cedar Rapids
Bowling Green
Monroe
Cumberland
Hagerstown
Wheaton
Rochester
Flowood
Springfield
St Louis
Omaha
Las Vegas
Freehold
Albuquerque
Brooklyn
Charlotte
Cincinnati
Columbus
Dayton
Middleburg Heights
Edmond
Tulsa
Duncansville
Wyomissing
Charleston
Austin
Carrollton
Corpus Christi
Cypress
Dallas
Houston
Katy
Lubbock
Mesquite
Victoria
Beckley
Clarksburg
Buenos Aires
Rosario
San Miguel de Tucumán
Victoria Park
Vienna
Liège
Plovdiv
Sofia
Victoria
Winnipeg
Edmonton
Rancagua
Santiago
Valdivia
Bogotá
Chía
Medellín
Osijek
Rijeka
Zagreb
Toulouse
Berlin
Cologne
Frankfurt am Main
Göttingen
Hamburg
Vogelsang-Gommern
Würzburg
Ayauta
Bunkyō City
Fukuoka
Higashihiroshima
Hiroshima
Izumo
Kagoshima
Katō
Kawagoe
Kita-Gun
Kumamoto
Kurume
Matsuyama
Miyazaki
Nagano
Nagasaki
Nagoya
Nishimuro-gun
Nishinomiya
Okayama
Osaka
Sapporo
Sasebo
Shibata
Shimonoseki
Shimotsuke
Shinjuku-ku
Sumida-ku
Takaoka,Toyama
Takasaki
Tokorozawa
Tokushima
Tomishiro
Tonami
Tsu
Ureshino
Yokohama
Alytus
Kaunas
Klaipėda
Šiauliai
Kuala Lumpur
Kuching
Cuernavaca
Guadalajara
Mexicali
Mérida
México
Morelia
San Luis de Potosi
Sneek
Bialystok
Bydgoszcz
Elblag
Lublin
Poznan
Ustroń
Warsaw
Lisbon
San Juan
Bucharest
Iași
Barnaul
Moscow
Novosibirsk
Omsk
Orenburg
Ryazan
Saint Petersburg
Saratov
Smolensk
Ulyanovsk
Yaroslavl
Belgrade
Kragujevac
Niška Banja
Cape Town
Port Elizabeth
Pretoria
Busan
Daegu
Daejeon
Gwangju
Incheon
Jeonju
Namdong-Gu
Seongnam-si
Seoul
Suwon
A Coruña
Barakaldo
Santander
Santiago de Compostela
Kaohsiung City
Taichung
Taipei
Kharkiv
Kyiv
Odesa
Vinnytsia
Zaporizhzhia
London
Wigan
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Janssen Research & Development, LLC
INDUSTRY